Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Atara Biotherapeutics Inc

ATRA ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$8.09

▼ -4.94%

Market Cap $81.21M · Vol 15.80K

Key Metrics

P/E Ratio

N/A

FWD: 104.20

Market Cap

$81.21M

Micro Cap

Div Yield

N/A

EPS Growth

-146.11%

YoY

RSI (14)

55.15

Momentum

Beta

0.10

vs Market

52W High

$19.10

57.64% below

52W Low

$3.92

106.38% above

Volume

15.80K

Avg 23.38K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

84.81%

Public shares

Shariah Compliance8 STANDARDS

✗ Atara Biotherapeutics Inc (ATRA) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ATRA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-4.26%

+0.62%

-15.64%

+81.80%

YTD

-55.28%

-30.97%

-82.41%

-97.40%

Financials & Valuation

TTM · Annual

Total Revenue	$120.77M
Net Income	$32.69M
Revenue Growth (YoY)	-96.42%
Gross Margin	82.44%
Operating Margin	43.53%
Net Profit Margin	27.07%
ROE	N/A
ROA · ROIC	50.60% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	104.20
PEG Ratio	0.06
P/S	1.90
P/B	N/A
P/FCF	N/A
EPS Growth	-146.11%
Outstanding Shares	10.04M

Technical Indicators

50-Day SMA	$9.37
200-Day SMA	$9.10
RSI (14)	55.15
Beta	0.10
52-Week High	$19.10
52-Week Low	$3.92

Volume Today	15.80K
Avg Daily Volume (30D)	23.38K
Relative Volume	0.68x
Volatility (10D)	61.68
Volatility (30D)	69.85
Free Float	84.81%

Analyst Consensus

BUY

Current Price $8.09

Mean Target $13.67

52W Low$3.92 52W High$19.10

Current

Target

$3.92 $19.10

Current Analyst target

+68.93% upside potential · 4 analysts

Identifiers

ExchangeNasdaq

FIGIBBG005Q3MR36

ISINUS0465132068

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.